CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.
Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Venetoclax 是一种针对抗凋亡蛋白 B 细胞淋巴瘤 2（BCL2）的选择性抑制剂，作为多发性骨髓瘤（MM）患者的靶向治疗药物。它最初于 2016 年 4 月获得美国食品药品监督管理局批准用于治疗慢性淋巴细胞白血病，随后于 2020 年 10 月获批用于急性髓系白血病。
然而，venetoclax 在伴有 t(11;14) 易位的复发/难治性多发性骨髓瘤（RRMM）患者亚组中被超说明书使用。临床前和临床研究强调了 venetoclax 在 MM 患者管理中的潜力，特别关注 t(11;14) 作为启动 venetoclax 为基础治疗的预测性生物标志物。随后，多项在 RRMM 患者中使用 venetoclax 联合地塞米松或/和蛋白酶体抑制剂的研究显示了有希望的结果，其中管理指南已将 venetoclax 列为治疗 MM 患者的选项之一。
因此，本综述聚焦于 venetoclax 在 RRMM 中的应用、临床疗效、安全性、给药策略以及启动 venetoclax 的预测性生物标志物。
此外，我们还讨论了正在研究 venetoclax 不同联合方案在 MM 患者中应用的进行中的研究。
Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatment of chronic lymphocytic leukemia in April 2016 and later for acute myeloid leukemia in October 2020.
However, venetoclax is used as an off-label in a subset group of relapsed and refractory multiple myeloma (RRMM) patients with the presence of translocation t(11;14). Preclinical and clinical studies have highlighted the potential of venetoclax in the management of MM patients, with a specific focus on t(11;14) as a predictive biomarker for initiating venetoclax-based treatment.
Later, several studies in RRMM patients that used venetoclax in combination with dexamethasone or/and proteasome inhibitors have shown promising results, in which management guidelines have included venetoclax as one of the options to treat MM patients. Hence, this review focuses on the use of venetoclax in RRMM, clinical efficacy, safety, dosing strategies, and predictive biomarkers for initiating venetoclax.
Additionally, we discuss ongoing studies that are investigating different combination of venetoclax regimens in MM patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
